In largest head-to-head randomized clinical trial evaluating the two medicines, Dovato (DTG/3TC) met the primary endpoint, demonstrating sustained non-inferior efficacy versus Biktarvy (BIC/FTC/TAF) ...
Data presented at HIV Glasgow from the DOLCE study demonstrates our commitment to offering effective 2-drug HIV regimens, for people living with advanced HIV A post-hoc analysis shows the 2-drug ...
Findings from the SEIMC-GeSIDA Foundation (FSG) PASO-DOBLE study will include treatment efficacy, safety, and weight gain experienced by participants taking Dovato ...
LONDON--(BUSINESS WIRE)-- ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, announces 48-week findings from PASO DOBLE (GeSIDA 11720 ...
The U.S. Food and Drug Administration this week approved Dovato, a two-drug combination pill that provides a complete once-daily antiretroviral regimen for people starting HIV treatment for the first ...
(RTTNews) - Specialist HIV company ViiV Healthcare Wednesday announced a positive data from PASO DOBLE phase IV randomized clinical trial of 2-drug regimen DOVATO compared to the 3-drug regimen ...
The two-drug regimen dolutegravir/lamivudine (DTG/3TC; Dovato) was just as effective as the three-drug regimen bictegravir/emtricitabine/tenofovir alafenamide ...
The MarketWatch News Department was not involved in the creation of this content. -- Largest head-to-head randomised clinical trial between DTG/3TC and BIC/FTC/TAF, conducted by SEIMC-GeSIDA ...
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced it will be presenting the largest head-to-head, randomised clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback